Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title" }, "data": [ { "type": "Grant", "id": "10724", "attributes": { "award_id": "1U01MD018294-01", "title": "You and Me Healthy: Testing Protocol", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 8046, "first_name": "Nathaniel", "last_name": "Stinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1116426, "principal_investigator": { "id": 26772, "first_name": "Emily Meredith", "last_name": "D'Agostino", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26773, "first_name": "Christoph", "last_name": "Hornik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "In the United States, >79 million people have been infected with SARS-CoV-2 and >900,000 died, but cases and deaths disproportionately affect underserved populations. Novel treatments early in disease may transform the pandemic’s course, but strategies that address disparities in timely testing and drug access are essential to maximize impact. Community driven interventions provided access to testing in underserved populations earlier in the pandemic, but need to be tailored to promote test and treat protocols and rapid access to treatment in response to current threats. This proposal will evaluate a systematic and scalable community- engaged test and treat protocol that provides rapid access to self-testing, “next steps” guidance, and local resources to facilitate treatment in underserved populations. We will evaluate a community engagement toolkit, You & Me Healthy Toolkit, developed based on our expertise and experience, to implement community-based test distribution and test and treat responses to the next phase of the COVID-19 pandemic in underserved populations. Our central hypothesis is that that the You & Me Healthy Toolkit will enable rapid design and implementation of a community driven, scientifically robust, and impactful COVID-19 test and treatment intervention. We will leverage successful partnerships and infrastructure established through two large national RADx-UP funded SARS-CoV2 testing and education interventions (SAY YES! COVID TEST, You & Me COVID-Free); an actively enrolling registry of participants interested in community-engaged research (You & Me Healthy Registry); partnerships with community engagement experts (Community Campus Partnerships for Health); and a history of collaboration with 150+ local community partners in Merced County, CA and Pitt County, NC with high proportion minority (Hispanic/Latino/Latinx and Black), high-poverty and low health insurance coverage. We will apply this toolkit to develop a rapid-deployment test and treat protocol implemented through our partners in two communities, launched in direct response to SARS-CoV2 infection surges or at community-identified high-risk events over a 15 month period. We will test this hypothesis through the following specific aims: 1) Evaluate the YMH toolkit ability to rapidly create effective academic- community research partnerships for promoting COVID-19 test access; 2) Document results of at-home tests using a community-engaged scalable reporting approach; 3) Evaluate ability of a test and treat protocol and local resourcing to facilitate timely access to testing, guidance, resource linkage, and therapeutics. This work will demonstrate the value of a generalizable toolkit to promote rapid and effective academic-community partnerships to enable timely testing and access to effective therapeutics in underserved populations in response to COVID-19 surges or transmission threats.", "keywords": [ "Address", "Affect", "Black race", "COVID test", "COVID-19", "COVID-19 disparity", "COVID-19 pandemic", "COVID-19 test", "COVID-19 testing", "COVID-19 therapeutics", "COVID-19 treatment", "Cessation of life", "Clinic", "Collaborations", "Communities", "County", "Disease", "Early treatment", "Economically Deprived Population", "Educational Intervention", "Enrollment", "Event", "Funding", "Geography", "Health", "Health Insurance", "Health Services Accessibility", "Health education", "High Prevalence", "Hispanic", "Home", "Infrastructure", "Insurance Coverage", "Intervention", "Latino", "Latinx", "Minority", "Participant", "Persons", "Pharmaceutical Preparations", "Pharmacy facility", "Phase", "Poverty", "Protocols documentation", "Public Health", "RADx Underserved Populations", "Recording of previous events", "Registries", "Reporting", "Research", "Research Design", "Resources", "Role", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Self Administration", "Technology", "Test Result", "Testing", "Therapeutic", "Time", "Transportation", "Trust", "Underserved Population", "United States", "Work", "antigen test", "base", "community based participatory research", "community engaged research", "community engagement", "community partnership", "coronavirus disease", "design", "disadvantaged population", "disparity reduction", "experience", "health disparity", "high risk", "home test", "improved", "interest", "multidisciplinary", "novel", "pandemic disease", "public health intervention", "rapid test", "response", "self testing", "testing access", "therapeutically effective", "transmission process", "underserved community", "web portal" ], "approved": true } }, { "type": "Grant", "id": "14197", "attributes": { "award_id": "3U01MD018294-01S1", "title": "You and Me Healthy: Testing Protocol", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 8046, "first_name": "Nathaniel", "last_name": "Stinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1096719, "principal_investigator": { "id": 26772, "first_name": "Emily Meredith", "last_name": "D'Agostino", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26773, "first_name": "Christoph", "last_name": "Hornik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "In the United States, >79 million people have been infected with SARS-CoV-2 and >900,000 died, but cases and deaths disproportionately affect underserved populations. Novel treatments early in disease may transform the pandemic’s course, but strategies that address disparities in timely testing and drug access are essential to maximize impact. Community driven interventions provided access to testing in underserved populations earlier in the pandemic, but need to be tailored to promote test and treat protocols and rapid access to treatment in response to current threats. This proposal will evaluate a systematic and scalable community- engaged test and treat protocol that provides rapid access to self-testing, “next steps” guidance, and local resources to facilitate treatment in underserved populations. We will evaluate a community engagement toolkit, You & Me Healthy Toolkit, developed based on our expertise and experience, to implement community-based test distribution and test and treat responses to the next phase of the COVID-19 pandemic in underserved populations. Our central hypothesis is that that the You & Me Healthy Toolkit will enable rapid design and implementation of a community driven, scientifically robust, and impactful COVID-19 test and treatment intervention. We will leverage successful partnerships and infrastructure established through two large national RADx-UP funded SARS-CoV2 testing and education interventions (SAY YES! COVID TEST, You & Me COVID-Free); an actively enrolling registry of participants interested in community-engaged research (You & Me Healthy Registry); partnerships with community engagement experts (Community Campus Partnerships for Health); and a history of collaboration with 150+ local community partners in Merced County, CA and Pitt County, NC with high proportion minority (Hispanic/Latino/Latinx and Black), high-poverty and low health insurance coverage. We will apply this toolkit to develop a rapid-deployment test and treat protocol implemented through our partners in two communities, launched in direct response to SARS-CoV2 infection surges or at community-identified high-risk events over a 15 month period. We will test this hypothesis through the following specific aims: 1) Evaluate the YMH toolkit ability to rapidly create effective academic- community research partnerships for promoting COVID-19 test access; 2) Document results of at-home tests using a community-engaged scalable reporting approach; 3) Evaluate ability of a test and treat protocol and local resourcing to facilitate timely access to testing, guidance, resource linkage, and therapeutics. This work will demonstrate the value of a generalizable toolkit to promote rapid and effective academic-community partnerships to enable timely testing and access to effective therapeutics in underserved populations in response to COVID-19 surges or transmission threats.", "keywords": [ "Address", "Affect", "Black race", "COVID test", "COVID-19", "COVID-19 disparity", "COVID-19 pandemic", "COVID-19 test", "COVID-19 testing", "COVID-19 therapeutics", "COVID-19 treatment", "Cessation of life", "Clinic", "Collaborations", "Communities", "County", "Disease", "Disparity", "Early treatment", "Economically Deprived Population", "Educational Intervention", "Enrollment", "Event", "Funding", "Geography", "Health", "Health Insurance", "Health Services Accessibility", "Health education", "High Prevalence", "Hispanic", "Home", "Infrastructure", "Insurance Coverage", "Intervention", "Latino", "Latinx", "Minority", "Participant", "Persons", "Pharmaceutical Preparations", "Pharmacy facility", "Phase", "Poverty", "Protocols documentation", "Public Health", "RADx Underserved Populations", "Recording of previous events", "Registries", "Reporting", "Research", "Research Design", "Resources", "Role", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Self Administration", "Technology", "Test Result", "Testing", "Therapeutic", "Time", "Transportation", "Trust", "Underserved Population", "United States", "Work", "antigen test", "community based participatory research", "community engaged research", "community engagement", "community partnership", "community setting", "coronavirus disease", "design", "disparity reduction", "experience", "health disparity", "high risk", "home test", "improved", "interest", "multidisciplinary", "novel", "pandemic disease", "pandemic potential", "pandemic response", "public health intervention", "rapid test", "response", "self testing", "testing access", "therapeutically effective", "transmission process", "underserved community", "web portal" ], "approved": true } }, { "type": "Grant", "id": "14783", "attributes": { "award_id": "5R01GM147211-02", "title": "YloC, a new ribonuclease of Bacillus subtilis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27797, "first_name": "Michael T.", "last_name": "Bender", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-04-30", "award_amount": 319410, "principal_investigator": { "id": 27991, "first_name": "DAVID H", "last_name": "BECHHOFER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: Our laboratory has, for many years, studied the essential process of mRNA decay in the model Gram-positive bacterium, Bacillus subtilis. We have identified several ribonuclease (RNase) enzymes of B. subtilis and have elucidated the role they play in mRNA turnover. The viability of a B. subtilis strain lacking all of the known 3’-to-5’ exoribonucleases prompted us to pursue identification of additional RNase activities. Using classic protein biochemistry, we recently identified a novel RNase, named YloC. YloC is an endoribonuclease with a hexameric structure, an unusual characteristic that is shared with only one other RNase: the Nsp15 protein of the SARS-CoV family. Initial experiments suggest that, although YloC has ribonuclease activity in vitro, it may function as an adapter for RNA interactions in vivo. Although proteins with significant homology to YloC are widespread in bacterial species, there is no published information on the structure of any member of this protein family. The current proposal seeks to elucidate the structure and function of YloC, as follows: • Mutagenize highly conserved residues of YloC to determine the effect on several properties – including ribonuclease activity, RNA binding, and structure – and to clarify functional domains of the protein. • Identify high-affinity RNA ligands of YloC via SELEX procedures with random-sequence oligonucleotides and with genomic RNA sequences. • Characterize how the strong interaction of YloC with E. coli polynucleotide phosphorylase (PNPase) acts in small RNA (sRNA) regulation in E. coli and possibly in B. subtilis. • Determine the three-dimensional structure of the highly homologous E. coli YicC protein bound to an RNA substrate, as well as the structure of YloC and/or its homologs from thermophilic bacterial species. This work will build on an initial determination of the structure of YicC. RELEVANCE: Ribonucleases play essential roles in RNA turnover and processing. A thorough understanding of the proteins that bind to and act enzymatically on RNA molecules will enable design of antimicrobial agents that disrupt such proteins and thereby interfere with bacterial cell growth.", "keywords": [ "5&apos", "-exoribonuclease", "Adaptor Signaling Protein", "Affect", "Affinity", "Alanine", "Awareness", "Bacillus subtilis", "Bacteria", "Binding", "Binding Proteins", "Biochemical", "Biological Assay", "Biological Process", "Biology", "Biophysics", "C-terminal", "Catalysis", "Cells", "Characteristics", "Code", "Coronavirus", "Endoribonucleases", "Enzyme Inhibition", "Enzymes", "Escherichia coli", "Exonuclease", "Family", "Family member", "Gene Deletion", "Genes", "Gram-Positive Bacteria", "Homologous Gene", "In Vitro", "Laboratories", "Ligands", "Messenger RNA", "Modeling", "Mutagens", "N-terminal", "Names", "Nucleotides", "Oligonucleotides", "Organism", "Outcome", "Pancreatic ribonuclease", "Physiological Processes", "Play", "Polyribonucleotide Nucleotidyltransferase", "Procedures", "Process", "Property", "Protein Biochemistry", "Protein Family", "Proteins", "Publishing", "RNA", "RNA Binding", "RNA Sequences", "RNA chemical synthesis", "Regulation", "Regulatory Element", "Reporting", "Ribonucleases", "Role", "SARS coronavirus", "Sequence Homology", "Small RNA", "Specific qualifier value", "Specificity", "Structure", "Tertiary Protein Structure", "Testing", "Transcript", "Virulence", "Work", "anti-microbial drug", "antibiotic design", "cell growth", "design", "endonuclease", "environmental change", "experimental study", "follow-up", "genome-wide", "genomic RNA", "in vitro activity", "in vivo", "insight", "mRNA Decay", "member", "microorganism", "model organism", "mutant", "novel", "poly A specific exoribonuclease", "prototype", "recruit", "response", "thermophilic organism", "three dimensional structure" ], "approved": true } }, { "type": "Grant", "id": "12130", "attributes": { "award_id": "1R01GM147211-01A1", "title": "YloC, a new ribonuclease of Bacillus subtilis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27797, "first_name": "Michael T.", "last_name": "Bender", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-04-30", "award_amount": 354900, "principal_investigator": { "id": 27991, "first_name": "DAVID H", "last_name": "BECHHOFER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: Our laboratory has, for many years, studied the essential process of mRNA decay in the model Gram-positive bacterium, Bacillus subtilis. We have identified several ribonuclease (RNase) enzymes of B. subtilis and have elucidated the role they play in mRNA turnover. The viability of a B. subtilis strain lacking all of the known 3’-to-5’ exoribonucleases prompted us to pursue identification of additional RNase activities. Using classic protein biochemistry, we recently identified a novel RNase, named YloC. YloC is an endoribonuclease with a hexameric structure, an unusual characteristic that is shared with only one other RNase: the Nsp15 protein of the SARS-CoV family. Initial experiments suggest that, although YloC has ribonuclease activity in vitro, it may function as an adapter for RNA interactions in vivo. Although proteins with significant homology to YloC are widespread in bacterial species, there is no published information on the structure of any member of this protein family. The current proposal seeks to elucidate the structure and function of YloC, as follows: • Mutagenize highly conserved residues of YloC to determine the effect on several properties – including ribonuclease activity, RNA binding, and structure – and to clarify functional domains of the protein. • Identify high-affinity RNA ligands of YloC via SELEX procedures with random-sequence oligonucleotides and with genomic RNA sequences. • Characterize how the strong interaction of YloC with E. coli polynucleotide phosphorylase (PNPase) acts in small RNA (sRNA) regulation in E. coli and possibly in B. subtilis. • Determine the three-dimensional structure of the highly homologous E. coli YicC protein bound to an RNA substrate, as well as the structure of YloC and/or its homologs from thermophilic bacterial species. This work will build on an initial determination of the structure of YicC. RELEVANCE: Ribonucleases play essential roles in RNA turnover and processing. A thorough understanding of the proteins that bind to and act enzymatically on RNA molecules will enable design of antimicrobial agents that disrupt such proteins and thereby interfere with bacterial cell growth.", "keywords": [ "5&apos", "-exoribonuclease", "Adaptor Signaling Protein", "Affect", "Affinity", "Alanine", "Awareness", "Bacillus subtilis", "Bacteria", "Binding", "Binding Proteins", "Biochemical", "Biological Assay", "Biological Process", "Biology", "Biophysics", "C-terminal", "Catalysis", "Cells", "Characteristics", "Code", "Coronavirus", "Endoribonucleases", "Enzyme Inhibition", "Enzymes", "Escherichia coli", "Exonuclease", "Family", "Family member", "Gene Deletion", "Genes", "Gram-Positive Bacteria", "Homologous Gene", "In Vitro", "Laboratories", "Ligands", "Messenger RNA", "Modeling", "Mutagens", "N-terminal", "Names", "Nucleotides", "Oligonucleotides", "Organism", "Outcome", "Pancreatic ribonuclease", "Physiological Processes", "Play", "Polyribonucleotide Nucleotidyltransferase", "Procedures", "Process", "Property", "Protein Biochemistry", "Protein Family", "Proteins", "Publishing", "RNA", "RNA Binding", "RNA Sequences", "RNA chemical synthesis", "Regulation", "Regulatory Element", "Reporting", "Ribonucleases", "Role", "SARS coronavirus", "Sequence Homology", "Small RNA", "Specific qualifier value", "Specificity", "Structure", "Tertiary Protein Structure", "Testing", "Transcript", "Virulence", "Work", "antibiotic design", "antimicrobial drug", "cell growth", "design", "endonuclease", "environmental change", "experimental study", "follow-up", "genome-wide", "genomic RNA", "in vitro activity", "in vivo", "insight", "mRNA Decay", "member", "microorganism", "model organism", "mutant", "novel", "poly A specific exoribonuclease", "prototype", "recruit", "response", "thermophilic organism", "three dimensional structure" ], "approved": true } }, { "type": "Grant", "id": "10810", "attributes": { "award_id": "1U24NS129500-01", "title": "Yale-METRO Metropolitan Emergency Trial netwoRK to advance patient Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)", "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22417, "first_name": "MARIA CAROLINA", "last_name": "Mendoza-Puccini", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-02-01", "end_date": "2028-01-31", "award_amount": 500854, "principal_investigator": { "id": 21588, "first_name": "Gail", "last_name": "D'Onofrio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23279, "first_name": "Kevin Navin", "last_name": "Sheth", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The Yale-Metropolitan Emergency Trial network to advance patient Outcomes (Yale-METRO) is anchored by Yale New Haven Health System (YNHHS) as the Hub and 5 leading partner integrated health systems (1) Hartford Healthcare, (2) Rhode Island/Brown University Health System, (3) Mount Sinai Health System, (4) New York Presbyterian/Weill Cornell Medicine, and (5) Montefiore Health System. Yale-New Haven Hospital is the 7th largest hospital in the U.S. and in collaboration with YNHHS and the Spokes with their respective networks these geographically proximate institutions, cover a densely populated catchment area including more than 8 million people throughout Connecticut, Rhode Island, Southeast NY, Southern MA, and 4 boroughs of New York City, with 1,739,027 Emergency Department visits offering access to a large and diverse population of acutely ill adult and pediatric patients. Principal Investigators Dr. Gail D'Onofrio (Emergency Medicine) and Dr. Kevin Sheth (Neurology) bring a complementary set of leadership skills, high-level clinical trial experience, and an excellent organizational framework. Each have demonstrated expertise in leading and conducting multicenter trials, and a proven track record of high-quality ED and pre-hospital recruitment, and retention in studies, even during the COVID-19 Pandemic. They have collaborated and are actively engaged in multicenter trials with the Spoke institutions and investigators. These interactions include leveraging successful contributions currently in place for NIH networks such as NeuroNEXT and Stroke Net. They have access to a cadre of impressive multispecialty faculty, creating a highly collaborative environment focused on the emergency care related to presentations and diagnoses of interest including, neurological, cardiovascular, respiratory, hematology and trauma. Finally, they have created mechanisms to facilitate enrollment 24 hours, 7 days a week that are already in place. The proposal is strengthened by a: (1) Pool of talented investigators with nationally recognized researchers and MPIs with experience implementing multicenter trials (2) Large diverse patient population (3) Informaticist and analytic team bringing innovative technological strategies and processes for rapid uptake of Spokes, recruitment, data collection, monitoring and quality; (4) Robust track record of mentoring junior investigators and (5) Expertise in developing future proposals for SIREN research. Yale-METRO offers all the components for conducting high-quality research and unique opportunities to use innovative technology advances for disease detection, patient enrollment, data collection and high-quality assurances procedures. Thus, Yale-METRO offers unique opportunities to strengthen the SIREN Network, designing, testing, and discovering interventions and therapies improving patient outcomes.", "keywords": [ "Acute", "Adult", "Agreement", "Applications Grants", "Area", "Blood Vessels", "COVID-19 pandemic", "Cardiac", "Cardiovascular system", "Caring", "Catchment Area", "Cessation of life", "Clinical", "Clinical Trials", "Clinical Trials Network", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Connecticut", "Data", "Data Collection", "Data Coordinating Center", "Detection", "Diagnosis", "Electronics", "Emergency Care", "Emergency Department Physician", "Emergency Medicine", "Emergency Situation", "Emergency department visit", "Enrollment", "Ensure", "Faculty", "Funding", "Future", "Generations", "Geography", "Health", "Health system", "Healthcare", "Hematologist", "Hematology", "Home", "Hospitals", "Hour", "Injury", "Institution", "Institutional Review Boards", "Integrated Health Care Systems", "Intervention", "Lead", "Leadership", "Life", "Long-Term Care", "Longterm Follow-up", "Lung", "Massachusetts", "Medicine", "Mentors", "Monitor", "Morbidity - disease rate", "Multicenter Trials", "Neurologic", "Neurologist", "Neurology", "Neurosurgeon", "New England", "New York", "New York City", "Outcome", "Patient-Focused Outcomes", "Pediatric Hospitals", "Persons", "Population", "Population Heterogeneity", "Prehospital Emergency Care", "Presbyterian Church", "Principal Investigator", "Procedures", "Process", "Quality Control", "Reporting", "Research", "Research Personnel", "Research Proposals", "Rhode Island", "Scientist", "Seasons", "Stroke", "Surgeon", "System", "Talents", "Technology", "Testing", "Time", "Training", "Trauma", "United States National Institutes of Health", "Universities", "Vision", "advanced disease", "clinical center", "collaborative environment", "data management", "data standards", "design", "disability", "experience", "improved", "innovation", "innovative technologies", "interest", "medical specialties", "metropolitan", "multidisciplinary", "participant enrollment", "patient population", "pediatric emergency", "pediatric patients", "quality assurance", "recruit", "respiratory", "skills", "success", "synergism", "uptake" ], "approved": true } }, { "type": "Grant", "id": "9902", "attributes": { "award_id": "5T03OH008607-18", "title": "Yale Occupational and Environmental Medicine Residency Training Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24278, "first_name": "ELIZABETH", "last_name": "MAPLES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 237365, "principal_investigator": { "id": 24279, "first_name": "CARRIE A", "last_name": "REDLICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The Yale Occupational and Environmental Medicine (OEM) residency training program, based in the Department of Medicine at the Yale School of Medicine, is one of the oldest, most productive, stable and highly regarded occupational medicine residency training programs in the United States, training 66 OEM physicians over the past almost thirty-five years. There is an urgent need for OEM and public health / preventive medicine (PM) trained physicians in multiple settings across the U.S., further highlighted by the COVID-19 pandemic. The Yale OEM residency is an integrated two-year NIOSH-funded PM / OEM residency training program that is fully accredited by the Accreditation Council for Graduate Medical Education (ACGME), and leads to board eligibility for certification in PM and OEM by the American Board of Preventive Medicine as well as a Master of Public Health (MPH) Degree from the Yale School of Public Health. The program is currently approved for a total of four positions, two per year. Trainees admitted to the program are expected to have completed an initial ACGME accredited residency in an appropriate clinical specialty, typically Internal Medicine or Family Medicine. This NIOSH TPG 5-year renewal proposal describes the Yale OEM residency program. Highlighted are: 1) our success to date in training physicians for OEM careers, 2) our current OEM training program, which is continually evolving to meet changing needs, and 3) our plans for training future OEM physician leaders able to address the substantial challenges U.S. workers and employers will face in the future. The goal of Yale OEM Residency training program is to train physicians to be proficient in all aspects of the practice of occupational and environmental medicine, based on a sound fundamental knowledge of epidemiology, industrial hygiene, biostatistics, toxicology, human and organization behavior, clinical medicine, and evidence-based critical analysis. We train future physician leaders to serve in a range of OEM academic, clinical and public health roles, with a particular focus on developing skills as educators and scientific investigators, in preparation for successful academic careers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8512", "attributes": { "award_id": "2T03OH008607-17", "title": "Yale Occupational and Environmental Medicine Residency Training Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24278, "first_name": "ELIZABETH", "last_name": "MAPLES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 237365, "principal_investigator": { "id": 24279, "first_name": "CARRIE A", "last_name": "REDLICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The Yale Occupational and Environmental Medicine (OEM) residency training program, based in the Department of Medicine at the Yale School of Medicine, is one of the oldest, most productive, stable and highly regarded occupational medicine residency training programs in the United States, training 66 OEM physicians over the past almost thirty-five years. There is an urgent need for OEM and public health / preventive medicine (PM) trained physicians in multiple settings across the U.S., further highlighted by the COVID-19 pandemic. The Yale OEM residency is an integrated two-year NIOSH-funded PM / OEM residency training program that is fully accredited by the Accreditation Council for Graduate Medical Education (ACGME), and leads to board eligibility for certification in PM and OEM by the American Board of Preventive Medicine as well as a Master of Public Health (MPH) Degree from the Yale School of Public Health. The program is currently approved for a total of four positions, two per year. Trainees admitted to the program are expected to have completed an initial ACGME accredited residency in an appropriate clinical specialty, typically Internal Medicine or Family Medicine. This NIOSH TPG 5-year renewal proposal describes the Yale OEM residency program. Highlighted are: 1) our success to date in training physicians for OEM careers, 2) our current OEM training program, which is continually evolving to meet changing needs, and 3) our plans for training future OEM physician leaders able to address the substantial challenges U.S. workers and employers will face in the future. The goal of Yale OEM Residency training program is to train physicians to be proficient in all aspects of the practice of occupational and environmental medicine, based on a sound fundamental knowledge of epidemiology, industrial hygiene, biostatistics, toxicology, human and organization behavior, clinical medicine, and evidence-based critical analysis. We train future physician leaders to serve in a range of OEM academic, clinical and public health roles, with a particular focus on developing skills as educators and scientific investigators, in preparation for successful academic careers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15268", "attributes": { "award_id": "1R21DA061281-01", "title": "Xylazine exposure and transitions to low-frequency injecting and injection cessation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 31855, "first_name": "ERIN MARGARET", "last_name": "Parker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2026-07-31", "award_amount": 266742, "principal_investigator": { "id": 20756, "first_name": "Ryan", "last_name": "McNeil", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1422, "ror": "https://ror.org/0213rcc28", "name": "Simon Fraser University", "address": "", "city": "", "state": "BC", "zip": "", "country": "CANADA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: We propose a two-year qualitative study that will characterize transitions to low-frequency injecting and injection cessation among people using xylazine-adulterated fentanyl in one of the states (Connecticut) most impacted by this drug supply change. America's drug supply has grown become more volatile since the outset of the COVID-19 pandemic, particularly the proliferation of xylazine-adulterated fentanyl in Northeast and Mid-Atlantic states, and is driving drug-related harms, including increases in non-fatal and fatal overdoses and severe injection-related soft tissue infections. Amidst the emergence of xylazine-adulterated fentanyl, researchers have begun to document reductions in injection drug use and injection cessation among people continuing to use fentanyl. Transitions to low-frequency injecting and injection cessation represent key strategies for reducing the potential for soft tissue infections associated with xylazine-injecting, as well as the transmission of infectious diseases (e.g., hepatitis C, HIV). However, the growing proportion of overdose deaths across the country attributed to non-injection drug use raise significant concerns about overdose awareness and the responsiveness of harm reduction services to the needs of people transitioning to low-frequency injecting and injection cessation. Contextualized understandings of how the proliferation of xylazine-adulterated fentanyl intersects with social, structural, and environmental influences to shape these transitions to low-frequency injecting and infection cessation and their implications for harm reduction services are urgently needed to optimize harm reduction approaches. Building on our extensive experience studying the impacts of drug supply changes, including on drug use behaviors and harm reduction services, we propose the following specific aims: Aim 1: To characterize how exposure to xylazine-adulterated fentanyl intersects with social-structural influences (e.g., homelessness, poverty) to shape transitions to low-frequency injecting (≤10 times per month) and injection cessation (>30 days). Aim 2: To explore perceptions of overdose vulnerability associated with non-injection drug use of xylazine-adulterated fentanyl, and examine their implications for overdose prevention messaging and harm reduction service delivery. Aim 3: To explore challenges and opportunities for harm reduction strategies, including syringe exchange, naloxone, and community health programs, in addressing overdose vulnerability among people exposed to xylazine-adulterated fentanyl transitioning to low-frequency injection drug use or injection cessation. Informed by the equity-focused Intersectional Risk Environment framework, we will conduct qualitative interviews with people using xylazine-adulterated fentanyl across Connecticut (n=50) who have transitioned to low-frequency injecting or injection cessation (Aims 1&2), as well as focus groups with harm reduction workers (n=30) from across the state (Aim 3). Findings will be mobilized to develop evidence-informed, scalable research, policy and program recommendations to address harms associated with xylazine-adulterated fentanyl, including the design of new interventions.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6558", "attributes": { "award_id": "3U54MD007595-14S2", "title": "Xavier RCMI Renewal Application-Overall", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 21971, "first_name": "Rina", "last_name": "Das", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2009-09-24", "end_date": "2023-12-31", "award_amount": 373357, "principal_investigator": { "id": 21972, "first_name": "Gene", "last_name": "D'Amour", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 21973, "first_name": "Guangdi", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 487, "ror": "https://ror.org/0085d9t86", "name": "Xavier University of Louisiana", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "To sustain Xavier’s overall research momentum, enhance research capacity, and advance to the next level of excellence in biomedical research on minority health and health disparities, the RCMI Cancer Research Center will implement program activities to support early stage, underrepresented investigators, maintain core facilities to support Xavier researchers at all levels of career development, and to promote and sustain long-lasting, bidirectional partnerships between Xavier and local communities to address cancer health disparities. The proposed RCMI Center will consist of three major research projects in two areas: basic biomedical research and behavioral research, and 4 Cores: the Administrative Core, the Investigator Development Core, the Research Infrastructure Core, and the Community Engagement Core. These programs will be implemented to achieve the following specific aims: Aim 1. Enhance Xavier’s research capacity for basic biomedical and behavioral research. The RCMI program will maintain, strengthen and optimize core services in support of Xavier investigators. Core facilities will be restructured, consolidated, and operations will be streamlined to maximize productivity and efficiency of Xavier’s ongoing research projects. Aim 2. Enable Xavier investigators to become more competitive in obtaining external funding. This will be achieved by 1) supporting two research projects in the basic biomedical area and one research project in the behavioral research area to enable these project PIs to become competitive in R01 applications; 2) providing critical research resources such as shared state-of-the-art instrumentation required in a competitive research project through the Research Infrastructure Core; 3) providing, through the Investigator Development Core, pilot funding to obtain necessary preliminary data for development of fundable research proposals; and 4) providing grantsmanship training through grant writing workshops and professional review services. Aim 3. Promote career enhancement of Xavier’s new and early stage investigators through a pilot project fund and by initiating a research/grantsmanship “pipeline” supporting new faculty for five years to obtain extramural funding. Aim 4. Enhance the quality of all scientific inquiry and promote research on minority health and health disparities by semi-annual symposiums and workshops on the quality of minority health and health disparities research each year to offer training in good scientific practices, appropriate statistical usage, and responsible laboratory practices for researchers at all levels. Working through the Community Engagement Core and the Investigator Development Core, the RCMI program will foster close interactions and collaborations among basic and behavior researchers, clinicians, and community stakeholders. Aim 5. Establish sustainable relationships with community-based organizations that will partner with Xavier researchers. A Community Engagement Core will be established to 1) promote and sustain community-academic partnerships through bidirectional knowledge sharing on intervention strategies and scientific discovery in cancer health disparities; 2) facilitate greater community involvement in setting research priorities and creating more opportunities for academic-practitioner-community research partnerships; 3) build capacity (knowledge and skills) among research investigators, community members, health systems, and potential research participants to conduct innovative and transformative research that addresses community health needs; 4) provide support for investigators to better disseminate research findings to the scientific community, community organizations, and lay communities.", "keywords": [ "Address", "African American", "Area", "Basic Science", "Behavior", "Behavioral Research", "Bioinformatics", "Biological", "Biomedical Research", "Biometry", "Collaborations", "Communities", "Community Health", "Core Facility", "Critiques", "Data", "Development", "Drug Delivery Systems", "Educational workshop", "Evaluation", "Extramural Activities", "Faculty", "Fostering", "Funding", "Grant", "Health Disparities Research", "Health system", "Intervention", "Knowledge", "Laboratories", "Louisiana", "Low income", "Malignant Neoplasms", "Mentors", "Minority", "Minority Health Research", "Modeling", "NCI Center for Cancer Research", "Neighborhoods", "Oncology", "Participant", "Peer Review", "Pilot Projects", "Productivity", "Published Comment", "Research", "Research Infrastructure", "Research Personnel", "Research Priority", "Research Project Grants", "Research Proposals", "Resources", "Scientific Inquiry", "Services", "System", "Therapeutic Agents", "Training", "Translating", "United States National Institutes of Health", "Universities", "Work", "Writing", "anticancer research", "base", "cancer health disparity", "career", "career development", "community based participatory research", "community engagement", "community involvement", "community organizations", "design", "health disparity", "innovation", "instrumentation", "member", "minority health", "operation", "programs", "service delivery", "skills", "success", "symposium", "tool" ], "approved": true } }, { "type": "Grant", "id": "7797", "attributes": { "award_id": "3P50HD103525-01S1", "title": "WUIDDRC Supplement-Supporting the health and well-being of children with intellectual and developmental disability during COVID-19 pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22578, "first_name": "Melissa", "last_name": "Parisi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-28", "end_date": "2025-05-31", "award_amount": 3734054, "principal_investigator": { "id": 23610, "first_name": "JOHN N.", "last_name": "CONSTANTINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 10345, "first_name": "Christina", "last_name": "Gurnett", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, { "id": 10348, "first_name": "Jason", "last_name": "Newland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Children with intellectual and developmental disabilities (IDD) are at major risk of irreversible harm from the Coronavirus Infectious Diseases 2019 (COVID-19) pandemic, particularly those from underserved populations. Not only are they at dramatically higher risk of becoming infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and death from COVID-19, but children with IDD are vulnerable to the negative impact of school closure. School districts provide critical services beyond the education, including nutritional, social, therapy (physical, occupational, and speech-language) and healthcare services. Risks are heightened for children with IDD, as they are often unable to wear masks, practice social distancing and/or implement effective hand hygiene. Access to rapid and reliable SARS-CoV-2 testing is essential for children with IDD and school staff in order to safely return to school. Members of our research team have developed an innovative, scalable, low-cost method for SARS-CoV-2 testing using saliva samples. Investigators at the Washington University Intellectual and Developmental Disabilities Research Center (IDDRC@WUSTL), in collaboration with the University of Missouri-Kansas City Institute of Human Development and the Kennedy Krieger Institute in Maryland (which includes an IDDRC, the Maryland Center for Developmental Disabilities, and the Kennedy Krieger School Programs), are ideally positioned to determine the best implementation strategies to maximize use of a saliva-based SARS-CoV-2 diagnostic test for vulnerable children and school staff in a school setting. The IDDRC@WUSTL has a long-standing relationship with the Special School District (SSD) of St. Louis County, whose mission is to serve children with IDD, and the national network of the Association of University Centers on Disabilities (AUCD). First, we will determine the most effective messaging and implementation strategies to maximize weekly SARS-CoV-2 testing in a school setting. In this adaptive clinical trial, we will administer 52,000 diagnostic tests to students and school staff at SSD, whose student population is 48% Black. Second, we will measure national attitudes among parents/guardians of children with IDD and school staff regarding the impact of COVID-19 and the importance of SARS-CoV-2 testing. At the successful completion of this project, we will have improved the acceptance, adoption, and process for SARS-CoV-2 diagnostic testing in a school-based setting to enable delivery of critical educational activities for children with IDD in an underserved community. By identifying the most effective methods for SARS-CoV-2 testing in a vulnerable population of children with IDD, we will establish a blueprint for wider adoption of COVID-19 mitigation efforts, such as vaccination.", "keywords": [ "2019-nCoV", "Adoption", "Attitude", "Cessation of life", "Child", "Child Welfare", "Cities", "Clinical Trials", "Cognitive", "Collaborations", "Communicable Diseases", "Communities", "Coronavirus", "County", "Custom", "Detection", "Developmental Disabilities", "Diagnostic tests", "Education", "Educational Activities", "FDA approved", "Family", "Hand", "Health", "Human Development", "Hygiene", "Infection", "Institutes", "Institution", "Intellectual and Developmental Disabilities Research Centers", "Intellectual functioning disability", "Kansas", "Language", "Life", "Maryland", "Masks", "Measures", "Methods", "Microfluidics", "Mission", "Missouri", "Nutritional", "Occupational", "Parents", "Perception", "Personal Satisfaction", "Population", "Positioning Attribute", "Prevention strategy", "Process", "Protocols documentation", "Randomized", "Research", "Research Personnel", "Risk", "Saliva", "Sampling", "Schools", "Services", "Social Distance", "Speech", "Students", "Surveys", "Swab", "Testing", "Underserved Population", "Universities", "Vaccination", "Vulnerable Populations", "Washington", "base", "cost", "cost effective", "disability", "disorder prevention", "experience", "health care service", "high risk", "implementation research", "implementation strategy", "improved", "innovation", "member", "pandemic disease", "programs", "rapid detection", "school district", "social", "success", "teacher", "tool", "transmission process", "uptake" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1392, "count": 13920 } } }